The following is a summary of the Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript:
Financial Performance:
Celcuity reported a net loss of $29.8 million, or $0.70 per share for Q3 2024, compared to a net loss of $18.4 million, or $0.83 per share for Q3 2023.
Non-GAAP adjusted net loss was $27.6 million, or $0.65 per share, compared to $17.3 million, or $0.78 per share, year over year.
Research and development expenses increased to $27.6 million, primarily due to activities supporting ongoing clinical trials.
Business Progress:
The VIKTORIA-1 Phase III clinical trial evaluating gedatolisib in breast cancer is progressing with the PIK3CA wild-type cohort fully enrolled and the mutant cohort on track.
Plans are on track to enroll the first patient in the VIKTORIA-2 Phase III trial in Q2 2025, which evaluates gedatolisib in a first-line setting.
Phase Ib/II trial evaluating gedatolisib in metastatic castration-resistant prostate cancer is also ongoing, with expected preliminary data in Q2 2025.
Opportunities:
Potential market expansion with gedatolisib, targeting a peak revenue opportunity exceeding $2 billion if FDA approvals are granted for both PIK3CA wild-type and mutant populations.
Potential to establish a new standard of care in breast cancer management with a triplet regimen including gedatolisib, addressing three interconnected signaling pathways.
Favorable feedback on gedatolisib's IV route of administration, which could offer advantages in market access and therapy adherence.
Risks:
Delay in reaching the primary analysis event threshold for the clinical trial cohorts could impact the timeline for drug approval and market entry.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
